Natural killer cell lymphoma in a pediatric patient with inflammatory bowel disease

Pediatrics

Volumn 126, Issue 4, 2010, Pages

  Deneau, Mark ^a   Wallentine, Jeremy ^a   Guthery, Stephen ^a   O'Gorman, Molly ^a   Bohnsack, John ^a   Fluchel, Mark ^a   Bezzant, John ^b   Pohl, John F ^a  

^a PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Colitis; Infliximab; Lymphoma; NK cell; Periodic fever

Indexed keywords

CD3 ANTIGEN; CD30 ANTIGEN; CD56 ANTIGEN; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ARTICLE; CASE REPORT; CELL INFILTRATION; CELL POPULATION; CHILD; CLINICAL FEATURE; ENTERITIS; EPSTEIN BARR VIRUS; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; LYMPHOID CELL; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; QUALITY OF LIFE; SCHOOL CHILD; SKIN BIOPSY; T CELL LYMPHOMA; COMPLICATION; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; LYMPHOMA, EXTRANODAL NK-T-CELL;

ANTIBODIES, MONOCLONAL; CHILD; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77957695494     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2010-0486     Document Type: Article

References (25)

1. Hanauer SB, Feagan BG, Lichtenstein GR, et al; ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet. 2002;359(9317):1541
2. Bonner GF. Managing the glucocorticoid dependent inflammatory bowel disease patient. Semin Gastrointest Dis. 2001;12(4):237-244 (Pubitemid 33027468)
3. Bickston SJ, Lichtenstein GR, Arseneau KO, Cohen RB, Cominelli F. The relationship between infliximab treatment and lymphoma in Crohn's disease. Gastroenterology. 1999;117(6):1433-1437
4. Sands B. Crohn's disease. In: Feldman M, Friedman L, Brundt L., et al, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 8th ed. Philadelphia, PA: Saunders Elsevier; 2006:2459-2490
5. Moss AC, Kim KJ, Fernandez-Becker N, Cury D, Cheifetz AS. Impact of concomitant immunomodulator use on long-term outcomes in patients receiving scheduled maintenance infliximab. Dig Dis Sci. 2010;55(5):1413-1420
6. Lémann M, Mary JY, Duclos B, et al; Groupe d'Etude Therapeutique des Affections Inflammatoires du Tube Digestif (GETAID). Infliximab plus azathioprine for steroiddependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology. 2006;130(4):1054-1061
7. Hyams J, Crandall W, Kugathasan S, et al; REACH Study Group. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007;132(3):863-873
8. Aithal GP, Mansfield JC. Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment. Aliment Pharmacol Ther. 2001;15(8):1101-1108
9. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a metaanalysis. Clin Gastroenterol Hepatol. 2009;7(8):874-881
10. Kato T, Tanabe J, Kanemoto M, Kobayashi C, Morita S, Karahashi T. A case of extranodal NK/T-cell lymphoma, nasal type mimicking typical manifestations of adult-onset Still's disease (AOSD) with hemophagocytic syndrome: diagnostic consideration between malignant lymphoma without lymphadenopathy and AOSD. Mod Rheumatol. 2009;19(6):675-680
11. Takahashi N, Miura I, Chubachi A, Miura AB, Nakamura S. A clinicopathological study of 20 patients with T/natural killer (NK)-cell lymphoma-associated hemophagocytic syndrome with special reference to nasal and nasal-type NK/T-cell lymphoma. Int J Hematol. 2001;74(3):303-308 (Pubitemid 33760087)
12. Kohrt H, Advani R. Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment. Leuk Lymphoma. 2009;50(11):1773-1784
13. Kobayashi R, Yamato K, Tanaka F, et al; Lymphoma Committee, Japanese Pediatric Leukemia/Lymphoma Study Group. Retrospective analysis of non-anaplastic peripheral T-cell lymphoma in pediatric patients in Japan. Pediatr Blood Cancer. 2010;54(2):212-215
14. Tai CF, Chang LY, Lin DT, Lin KH, Jou ST, Yang YL. A case of natural killer cell lymphoma presenting with bilateral pleural effusions and hemophagocytic lymphohistocytosis. Pediatr Blood Cancer. 2009;52(5):666-669
15. Mehta PA, Davies SM, Kumar A, et al; Children's Oncology Group. Perforin polymorphism A91V and susceptibility to B-precursor childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Leukemia. 2006;20(9):1539-1541
16. + T/NK cell lymphoma of the colon. J Gastroenterol. 2002;37(11):939-946
17. US Food and Drug Administration. FDA alert: Information on tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi). August 4, 2009. Available at: www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm109340.htm. Accessed September 10, 2009
18. Gruhne B, Sompallae R, Masucci MG. Three Epstein-Barr virus latency proteins independently promote genomic instability by inducing DNA damage, inhibiting DNA repair and inactivating cell cycle checkpoints. Oncogene. 2009;28(45):3997-4008
19. Graham JP, Moore CR, Bishop GA. Roles of the TRAF2/3 binding site in differential B cell signaling by CD40 and its viral oncogenic mimic, LMP1. J Immunol. 2009;183(5):2966-2973
20. Omori N, Narai H, Tanaka T, et al. Epstein-Barr virus-associated T/NK cell-type central nervous system lymphoma which manifested as a post-transplantation lymphoproliferative disorder in a renal transplant recipient. J Neurooncol. 2008;87(2):189-191
21. Guthery S, Heubi J, Bucuvalas J, et al. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. Transplantation. 2003;75(7):987-993 (Pubitemid 36438527)
22. Higgins C, Swerdlow A, Smith J, et al. Risk of lymphoid neoplasia after cardiothoracic transplantation: the influence of underlying disease and human leukocyte antigen type and matching. Transplantation. 2003;75(10):1698-1703
23. Guthery S, Gross T. Assessing the risk of Epstein-Barr virus-related lymphoproliferative disorders before administration of visilizumab. Gastroenterology. 2008;134(3):895-896
24. Friedman S. Cancer in Crohn's disease. Gastroenterol Clin North Am. 2006;35(3):621-639
25. Baran-Marszak F, Laquillier C, Youlyouz I, et al. Effect of tumor necrosis factor alpha and infliximab on apoptosis of B lymphocytes infected or not with Epstein-Barr virus. Cytokine. 2006;33(6):337-345 (Pubitemid 43816308)